KRISTIN ATTIOGBE: Open Payments
NPI 1699055749 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,928 in 119 payments from 19 companies in 2025. Trend: 2023 $6,756 · 2024 $20,573 · 2025 $12,928
Consulting: $7,033Food & beverage: $3,739Travel & lodging: $1,784Honoraria: $372
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 6 | $2,937 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $2,530 |
| Janssen Biotech, Inc. | 20 | $1,890 |
| PFIZER INC. | 13 | $1,775 |
| Celltrion USA Inc. | 3 | $1,280 |
| ABBVIE INC. | 19 | $656 |
| Merck Sharp & Dohme LLC | 6 | $575 |
| Janssen Scientific Affairs, LLC | 2 | $250 |
| Lilly USA, LLC | 7 | $247 |
| GENZYME CORPORATION | 4 | $211 |
Products named: TREMFYA, VELSIPITY, ZYMFENTRA, RINVOQ, ENTYVIO, OMVOH, DUPIXENT, SKYRIZI.
Industry payments across MD — which companies pay providers there.
